The company starts a 2-year program to bring RxSelex closer to market
LONDON, UK, April 9, 2020 - AlphaBiomics Ltd. has been awarded an Invention for Innovation Product Development Award grant to validate RxSelex, its microbiome-based predictive diagnostic for response to biologic therapy in patients experiencing inflammatory bowel disease (IBD).
This 2-year program is funded by the National Institute for Health Research (NIHR). Working with renowned experts, AlphaBiomics will verify that the RxSelex machine learning algorithm correctly predicts biologic treatment response of patients in the United Kingdom and the Netherlands, and develop the laboratory tests and computer programs needed for RxSelex.
In addition, AlphaBiomics will determine the value of RxSelex for patients and for the UK National Health Service (NHS). Patients will be involved throughout to advise and guide the research, based on their invaluable insights and experiences.
These critical steps will place AlphaBiomics in a strong position to generate the evidence required to speed up RxSelex adoption by the NHS and healthcare systems globally, bringing relief to underserved patients experiencing IBD.